Direct answer
Clinical AI Report · October 7, 2026
Key takeaways
- DoseMeRx is a Bayesian precision dosing platform for hospital pharmacists and nephrologists, calculating individualized doses of narrow therapeutic index drugs from weight, renal function, drug levels and population pharmacokinetic models.
- DoseMeRx is sold on enterprise terms to hospitals and health systems, deployed through hospital pharmacy rather than by individual physicians, and reports use in 300+ hospitals worldwide (vendor figure).
- DoseMeRx supports AUC-guided vancomycin dosing as recommended by the 2020 ASHP/IDSA guideline, plus aminoglycosides, warfarin, tacrolimus, cyclosporine, phenytoin and valproate, with EHR integration for Epic, Cerner and Meditech.
- DoseMeRx needs drug level results and patient parameters for its best recommendations, works only for drugs with validated Bayesian models, and offers no differential diagnosis or literature search.
In this review
DoseMeRx at a glance
- Made by
- DoseMeRx, based in Brisbane, Australia, and Indianapolis, Indiana. Founded in 2012.
- Price
- Enterprise pricing for hospitals and health systems; not sold to individual physicians.
- Method
- Bayesian pharmacokinetic modeling from weight, renal function, drug levels and population pharmacokinetic models.
- Drugs covered
- Vancomycin; gentamicin, tobramycin and amikacin; warfarin; tacrolimus and cyclosporine; phenytoin and valproate.
- Guideline support
- AUC-guided vancomycin dosing, which the 2020 ASHP/IDSA guideline recommends with Bayesian software in place of trough-only monitoring. ASHP/IDSA, 2020
- Hospitals
- 300+ hospitals worldwide (vendor figure). DoseMeRx
- EHR integration
- Epic, Cerner and Meditech.
- Deployment
- Led by hospital pharmacy rather than individual physicians.
- Inputs needed
- Drug level results and patient parameters for the best recommendations.
- Not included
- Differential diagnosis, literature search and general clinical decision support.
Who DoseMeRx is for
A good fit for
- Hospital pharmacy teams moving vancomycin monitoring from troughs to AUC-guided dosing
- Nephrology teams dosing narrow therapeutic index drugs in impaired or fluctuating renal function
- Health systems on Epic, Cerner or Meditech that want dosing support connected to the EHR
Look elsewhere if
- You are an individual physician without a hospital pharmacy program
- You need differential diagnosis, literature search or general clinical answers
- The drugs you dose most lack a validated Bayesian pharmacokinetic model
What is DoseMeRx?
DoseMeRx is a Bayesian precision dosing platform for hospitals. It calculates individualized doses of narrow therapeutic index drugs, such as vancomycin, aminoglycosides and immunosuppressants, from a patient’s weight, renal function and measured drug levels combined with population pharmacokinetic models, rather than relying on standard dosing tables. DoseMeRx reports use in 300+ hospitals worldwide (vendor figure).
Precision dosing matters most in nephrology, where fluctuating kidney function directly changes how quickly drugs are cleared. DoseMeRx was founded in 2012 and is based in Brisbane, Australia, and Indianapolis, Indiana. Hospital pharmacy usually leads deployment.
Does DoseMeRx support AUC-guided vancomycin dosing?
DoseMeRx supports AUC-guided vancomycin dosing, the approach in the 2020 ASHP/IDSA consensus guideline on vancomycin monitoring for serious MRSA infections. That guideline recommends Bayesian software for AUC-guided dosing in place of trough-only monitoring. DoseMeRx interprets measured vancomycin levels alongside renal function and other patient parameters to recommend an individualized dose.
Peer-reviewed studies report improved target attainment and less nephrotoxicity with Bayesian dosing than with traditional methods.
| Finding | Source | Type of evidence |
|---|---|---|
| Recommends Bayesian software for AUC-guided vancomycin dosing, replacing trough-only monitoring | Source: ASHP/IDSA, 2020 | Type of evidence: Consensus guideline |
| Compares Bayesian with standard vancomycin dosing | Source: Clinical Pharmacokinetics, 2023 | Type of evidence: Systematic review |
Which drugs can DoseMeRx dose?
DoseMeRx covers narrow therapeutic index drugs that have validated Bayesian pharmacokinetic models: vancomycin; the aminoglycosides gentamicin, tobramycin and amikacin; warfarin; the immunosuppressants tacrolimus and cyclosporine; and the antiepileptics phenytoin and valproate. Drugs without a validated model are outside its scope, so check that the drugs your hospital monitors most are covered.
How much does DoseMeRx cost?
DoseMeRx is sold on enterprise terms to hospitals and health systems, not to individual physicians. Deployment is usually led by hospital pharmacy rather than started by prescribers, so pharmacy and IT teams need to be involved in the purchase alongside the nephrology, infectious disease or other services that will use its dose recommendations.
Does DoseMeRx integrate with Epic?
DoseMeRx integrates with major EHR systems, including Epic, Cerner and Meditech. It needs drug level results and patient parameters such as weight and renal function for its best recommendations, so confirm during implementation which of those values flow in from the EHR automatically and which staff must enter by hand.
Strengths and limitations
Strengths
- Bayesian pharmacokinetic modeling for individualized precision dosing
- Guideline-concordant AUC-guided vancomycin dosing (2020 ASHP/IDSA)
- Covers vancomycin, aminoglycosides, anticoagulants, immunosuppressants, and more
- Deployed in 300+ hospitals worldwide
- EHR integration with major systems (Epic, Cerner, Meditech)
- Peer-reviewed evidence demonstrating improved target attainment
- Reduces nephrotoxicity from drug accumulation in renal impairment
- Real-time dose optimization based on drug levels and renal function
Limitations
- Enterprise-only pricing — not accessible to individual physicians
- Narrow focus on precision dosing — no differential diagnosis, literature search, or general CDS
- Requires drug level results and patient parameters for optimal recommendations
- Hospital pharmacy-driven deployment (not physician-initiated)
- Limited to drugs with validated Bayesian pharmacokinetic models
- Learning curve for clinicians unfamiliar with Bayesian dosing concepts
How DoseMeRx compares
DoseMeRx individualizes doses from measured drug levels. The tools below cover the questions around it, such as antimicrobial choice, standard dosing and interaction checks.
| Product | Price | Who can use it | How it differs |
|---|---|---|---|
| DoseMeRx | Price: Enterprise, for hospitals and health systems | Who can use it: Hospital pharmacy deployment | How it differs: Bayesian dosing from drug levels, including AUC-guided vancomycin |
| Vera Health | Price: Free for licensed clinicians and trainees | Who can use it: Outside the US except sanctioned countries (vendor) | How it differs: Cited answers plus a drug database for antimicrobial dosing and interaction checks |
| Epocrates | Price: Free basic app; Epocrates Plus $179.99 a year (October 2026) | Who can use it: Free registration | How it differs: Free drug monographs, dosing and a multi-drug interaction checker; no AI clinical reasoning in the free app |
| UpToDate | Price: $579 a year for one US clinician (October 2026) | Who can use it: Paid subscription; plans vary by country | How it differs: 12,000+ expert-written topics with GRADE-graded recommendations |
How Clinical AI Report rates DoseMeRx
82/100
Specialty review (nephrology); not part of the overall clinical rankings
DoseMeRx earns an Very Good rating in nephrology for its Bayesian precision dosing approach and adherence to ASHP/IDSA guidelines. It is a well-adopted platform for AUC-guided vancomycin dosing in patients with renal impairment.
- Clinical accuracy · 25%90
- Evidence and citations · 20%82
- Product design · 15%78
- EHR integration · 15%88
- Workflow and speed · 15%85
- Value and pricing · 10%58
How this review was researched
- Sources
- 3 sources, listed below, including the 2020 ASHP/IDSA vancomycin guideline, a 2023 systematic review in Clinical Pharmacokinetics and DoseMeRx’s website.
- Evidence labels
- Vendor claims are labelled as vendor figures. Independent studies and preprints are named, with their limits.
- What was not tested
- Clinical AI Report did not run its own accuracy test or measure time savings. The score is an editorial judgment against a published rubric, not a clinical benchmark.
- Independence
- Rankings are editorial opinions, not sponsored placements.
Read the scoring methodology, or send a correction.
DoseMeRx FAQ
Is DoseMeRx hard to learn?
There is a learning curve for clinicians unfamiliar with Bayesian dosing concepts. Plan training for prescribers and pharmacists who have only used standard dosing tables or trough-based vancomycin monitoring, since DoseMeRx works from drug levels and pharmacokinetic models instead.
Does DoseMeRx work without drug levels?
DoseMeRx gives its best recommendations when drug level results and patient parameters such as weight and renal function are available. It is built around interpreting measured levels, so hospitals that rarely draw levels for a given drug will get less from it for that drug.
Is DoseMeRx a general drug reference?
No. DoseMeRx is a precision dosing platform, not a general clinical decision-support or drug reference tool. It offers no differential diagnosis or literature search, so clinicians still need a reference such as Vera Health, Epocrates or UpToDate for broader drug and treatment questions.
Sources (3)
- Therapeutic Monitoring of Vancomycin for Serious MRSA Infections: A Revised Consensus Guideline · American Journal of Health-System Pharmacy (ASHP/IDSA), 2020
- Bayesian Versus Standard Dosing for Vancomycin: A Systematic Review · Clinical Pharmacokinetics, 2023
- DoseMeRx website · DoseMeRx